Dec 27, 2025 • MarketBeat
NEUTRAL
Rice Hall James & Associates LLC Makes New Investment in QuidelOrtho Corporation $QDEL
Rice Hall James & Associates LLC has made a new investment in QuidelOrtho Corporation (NASDAQ:QDEL) during the third quarter, acquiring 258,914 shares valued at approximately $7.63 million. Despite QuidelOrtho beating quarterly earnings estimates, it reported a negative net margin and carries a "Reduce" consensus analyst rating. Insiders, including the CEO and CFO, have recently increased their holdings in the company.
Dec 18, 2025 • Sahm
BULLISH
Innovating Diagnostics and What's Next
QuidelOrtho Corporation has released Episode 54 of its Science Bytes podcast, featuring Dr. Jonathan Siegrist, EVP of Research & Development and Chief Technology Officer. The episode, "2025 Diagnostic Trends and Innovations," discusses advancements in diagnostic solutions like high-sensitivity troponin testing, non-invasive assays for gastrointestinal health, rapid combo tests for respiratory surges, and the role of molecular platforms, informatics, and AI in personalized care. These innovations aim to streamline workflows, guide timely medical decisions, and improve patient outcomes globally.
Dec 18, 2025 • Finviz
BULLISH
Innovating Diagnostics and What's Next
QuidelOrtho Corporation has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, who discusses 2025 diagnostic trends and innovations. The episode highlights advancements in cardiac care, non-invasive solutions for gastrointestinal health, rapid combo tests for respiratory surges, and the role of molecular diagnostics, informatics, and AI in personalized care. These innovations aim to streamline workflows, guide timely decisions, and improve patient outcomes globally.
Dec 16, 2025 • MarketBeat
SOMEWHAT-BEARISH
QuidelOrtho Corporation (NASDAQ:QDEL) Given Consensus Recommendation of "Reduce" by Analysts
Analysts have issued a "Reduce" consensus rating for QuidelOrtho Corporation (NASDAQ:QDEL) based on ratings from seven brokerages, with an average one-year price target of $38.20. Despite recent insider stock purchases by the CEO and CFO, and QuidelOrtho beating quarterly earnings expectations, the company experienced a revenue decline of 3.7% year-over-year and reported a negative net margin. The FY2025 EPS guidance is also below sell-side consensus.
Dec 15, 2025 • Simply Wall Street
BULLISH
Why QuidelOrtho (QDEL) Is Up 6.0% After Beating Q3 Estimates And Raising Guidance
QuidelOrtho (QDEL) saw its stock rise by 6.0% after reporting third-quarter results that surpassed analyst expectations for both revenue and earnings, leading to an increase in its full-year guidance. This positive performance reinforces confidence in the company's execution, despite ongoing challenges related to declining high-margin COVID testing revenues and legacy product exits. The updated guidance, which projects full-year 2025 revenue between US$2.68 billion and US$2.74 billion, indicates that operational improvements and new offerings may offset the impact of discontinued products.
Dec 15, 2025 • Sahm
SOMEWHAT-BULLISH
Why QuidelOrtho (QDEL) Is Up 6.0% After Beating Q3 Estimates And Raising Guidance
QuidelOrtho (QDEL) saw its stock rise by 6.0% after reporting third-quarter results that surpassed analyst expectations for both revenue and earnings, leading the company to raise its full-year guidance. This positive performance reinforces confidence in management's execution despite the challenges of declining COVID testing revenue and legacy product discontinuations. Investors are watching to see if new offerings and operational improvements can offset these headwinds and support the company's projected long-term growth.